Should I give DAPT?

🔍	Deep Dive
📌	Clinical Application
🔸	Weak Evidence
🔹	Strong Evidence
📑	Evidence summaries
✅	Recommended treatment
⚠️	Critical Information
💡	Extra Reading
❗	Caveats

A patient with acute stroke arrives within the thrombolysis window. Stroke team activated. Imaging done. The patient is thrombolysed.

In many emergency departments, that's a well-oiled machine.

But what about the strokes you aren't thrombolysing?
That's where many of us hesitate.

"Call Neurology."

"Let's admit them first."

"The inpatient team can decide."

But why?

As emergency physicians, we make time-critical decisions every day. Starting dual antiplatelet therapy (DAPT) in the right patient is one of them.

So let's break it down.

Fair warning: this is going to be a long story of studies, trials, and references.
👉 If you're on shift and just want to know what to do, jump straight to the practical guide.
👉 And if even that is too much right now and you just want the bottom line, here's the 60-second version.

Otherwise, let's start at the beginning.

Why does it matter?

Our story begins in 1950. A general practitioner in California named Lawrence Craven made an observation: patients taking aspirin seemed less likely to develop myocardial infarction. Six years later, he extended the same idea to stroke [1].

Today, after more than 70 years of research and hundreds of clinical trials, we know he was right.

The first question researchers asked was:

Does aspirin actually help after an acute ischemic stroke?

📑

The answer came from two of the largest stroke trials ever conducted—the International Stroke Trial (IST) [2] and the Chinese Acute Stroke Trial (CAST) [3]. Together, they enrolled nearly 40,000 patients, and both showed that giving aspirin soon after an acute ischemic stroke reduced recurrent stroke and death.

So aspirin became standard of care.

Then we asked

Could blocking two pathways work even better?

📑

That question led to the CHANCE trial [4]. Patients with minor ischemic stroke or high-risk TIA received either aspirin alone or aspirin plus clopidogrel, started within 24 hours. Short-course dual antiplatelet therapy of 90 days reduced recurrent stroke without increasing major haemorrhage.

📑

The findings were then tested in the POINT trial [5]. Once again, DAPT reduced major ischemic events. This time, however, researchers also found a trade-off: major bleeding increased from 0.4% to 0.9%.

But both trials started DAPT within 24 hours. Did we really have to be that quick?

Could the window be stretched?

📑

The INSPIRES trial [6] showed that it could. Patients with presumed atherosclerotic minor stroke or high-risk TIA still benefited when DAPT was started within 72 hours, although this came with a small increase in moderate-to-severe bleeding.

More recently, a pooled analysis [7] helped refine the question of timing. The greatest benefit was seen when DAPT was started as early as possible, with the effect progressively declining after symptom onset and an apparent threshold at around 42 hours.

NIHSS is Not Disability

For decades, stroke treatment revolved around a single number.

In 1995, the landmark NINDS rt-PA Stroke Trial [8] established intravenous thrombolysis as an effective treatment for acute ischemic stroke. Along with it came the widespread use of the National Institutes of Health Stroke Scale (NIHSS) as a standardised way to quantify neurological deficit.

Soon, a dangerous shortcut emerged.

Low NIHSS meant minor stroke. Minor stroke meant less to worry about.

But while NIHSS is an excellent tool for measuring neurological impairment, it is a poor tool for measuring disability. The challenge is that disability is personal.

📌

A score of 2 may represent a trivial sensory deficit in one patient, yet end the career of a concert pianist, surgeon, or pilot in another. Stroke treatment should therefore be guided not only by the NIHSS, but by whether the deficit is disabling for that individual.

The 2026 AHA guidelines [9] make this explicit:

⚠️

“ Use of the NIHSS score alone does not suffice.”

Instead, we should ask a much more important question:

Is this deficit disabling for this patient?

That concept was highlighted by the PRISMS investigators [10], who created an operational definition for "clearly disabling"

Ask yourself:

If these deficits remain, will the patient still be able to perform basic activities of daily living or return to work? (In patients with NIHSS 0-5)

✅

Think BATHE:

Bathing
Ambulating
Toileting
Hygiene
Eating

This decision should be made in consultation with the patient and their family.

✅

Some deficits should almost always be considered disabling, regardless of the total NIHSS:

Complete hemianopia
Severe aphasia
Severe neglect
Weakness preventing sustained effort against gravity

But what about the truly non-disabling stroke?

Up to half of all ischemic strokes present with non-disabling symptoms [11].

These patients often look well enough to be discharged, yet they are not benign. Approximately 4–5% will deteriorate or develop a disabling stroke within the next 30 days [12].

Traditionally, these patients occupied a grey zone.

📑

Then came the ARAMIS trial [13]; they compared IV alteplase with DAPT in carefully selected patients with minor, non-disabling stroke.

DAPT was non-inferior in achieving excellent functional outcomes at 90 days, without increasing the risk of symptomatic intracranial haemorrhage.

The 2026 AHA guidelines [9] now say,

✅

“In eligible adult patients with AIS presenting with mild non-disabling stroke deficits within 4.5 hours of symptom onset or last known well, IVT is not recommended as it has not shown superiority in improving functional outcomes compared to double antiplatelet treatment [3B-R]”

Shifting the emphasis toward:

Rapid vascular imaging
Identification of high-risk features
Early secondary prevention
Prompt initiation of DAPT in appropriate patients

The question in the Emergency Department is therefore no longer: "Is the NIHSS low?"

Instead, ask two separate questions:

Is this stroke disabling? If yes, think reperfusion.
If it isn't disabling, does this patient qualify for early DAPT?

Risk Stratifying TIA

For years, the words "It's just a TIA" reassured both doctors and patients.

Then, in 2000, Johnston and colleagues [14] changed that forever.

📑

Their landmark study showed that nearly 10% of patients diagnosed with a TIA suffered an ischemic stroke within the next 90 days, and almost half of these strokes occurred within the first 48 hours.

Suddenly, TIA was a neurological emergency.

📑

The DOUBT study [15] reinforced this shift by demonstrating that 13% of patients whose symptoms lasted as little as five minutes already had evidence of infarction on MRI.

In other words, some patients labelled as having a TIA had actually sustained a stroke.

The next challenge was obvious.

How do we identify the patients most likely to deteriorate?

This led to the development of the ABCD² score, a simple bedside tool based on

✅

Age
Blood pressure
Clinical features
Duration of symptoms
Diabetes.

Josephson and colleagues demonstrated that patients judged to have a true TIA generally had higher ABCD² scores and that the risk of stroke increased as the score increased [16].

The ABCD² score rapidly became the most widely used TIA risk stratification tool, however, enthusiasm was soon tempered by its limitations.

It performs reasonably well at a population level but is less reliable when making decisions for the individual patient in front of you. Importantly, it ignores several of the strongest predictors of early stroke, including [17]

Large artery stenosis
Atrial fibrillation
Cervical artery dissection
Carotid web
Recurrent ("crescendo") TIAs
Posterior circulation symptoms such as ataxia, dysmetria, or isolated hemianopia

Criticism continued to mount.

📑

A large ED-based study of 2,056 subjects found that the ABCD² Score performed poorly in the acute setting [18].

In high-risk patients (score >5), the ABCD² Score was only 31.6% sensitive in identifying patients who suffered a stroke within 7 days.
This study found that the ABCD² Score was incorrectly calculated in the ED in 1/3 of patients.

A 2015 meta-analysis concluded that clinical judgment, along with the integration of certain clinical and imaging features, is more accurate for predicting the risk of cerebrovascular events [19].

Researchers therefore looked beyond purely clinical scoring systems.

The ABCD3 and ABCD3-I scores expanded on ABCD² by including recurrent TIAs, acute infarction on imaging, carotid stenosis, and eventually intracranial stenosis.

Yet despite these newer tools, ABCD² remains the most widely used bedside score worldwide.

✅

Recognising both its strengths and its limitations, the 2023 AHA Scientific Statement on TIA recommends that [17]

Risk stratification scores should be used to help identify high-risk patients and guide disposition.
Risk scores should never replace a comprehensive clinical assessment.
All patients with suspected TIA should undergo vascular imaging in the Emergency Department, regardless of their ABCD² score or whether they are admitted.

This explains why the 2026 AHA Acute Ischemic Stroke Guideline continues to define high-risk TIA as an ABCD² score ≥4 when recommending DAPT.

It is not because the ABCD² score is perfect. It is because it remains the best validated, most practical bedside tool, the one used in the landmark DAPT trials, and a common language understood by clinicians worldwide.

The evolution of antiplatelet therapy in TIA

Once clinicians recognised that the highest stroke risk occurred immediately after a TIA, another question emerged:

Could we prevent these early strokes with more aggressive antiplatelet therapy?

The first attempt was the MATCH trial [20]

Unfortunately, the results were disappointing. Although ischemic events were only marginally reduced, major bleeding increased significantly.

At first glance, it appeared that DAPT had failed. But the problem wasn't necessarily the drugs. It was the timing.

📑

Patients in MATCH had experienced their TIA or stroke up to six months earlier, long after the period of greatest recurrent stroke risk.

Then came the EXPRESS study [21]

📑

Patients were assessed urgently, and secondary prevention was started immediately. Early treatment reduced the risk of recurrent stroke by almost 80%, proving that speed mattered as much as the treatment itself.

This insight paved the way for the landmark FASTER [22], CHANCE [4], and POINT [5] trials.

📑

They demonstrated that:

The benefit of DAPT is greatest when started within 24–72 hours
Most of the benefit occurs during the first three weeks
Extending DAPT beyond this period provides little additional benefit while substantially increasing bleeding risk
A 1.5-3.5% decreased risk of stroke was found.

That is why modern guidelines recommend 21 days of dual antiplatelet therapy for appropriately selected patients with minor ischemic stroke or high-risk TIA, followed by lifelong single antiplatelet therapy.

How to decide on antiplatelet therapy?

Once you've diagnosed an acute ischemic stroke or TIA, deciding on antiplatelet therapy is relatively straightforward.

Rather than trying to memorise multiple guideline recommendations, ask yourself three questions:

Is this patient eligible for thrombolysis?
Is this a non-cardioembolic stroke?
Does this patient qualify for dual antiplatelet therapy (DAPT)?

Step 1. Is this patient eligible for thrombolysis?

Before reaching for aspirin or clopidogrel, determine whether the patient should receive reperfusion therapy.

The 2026 AHA guidelines recommend that [9]

✅

“In adult patients with AIS with disabling deficits, regardless of NIHSS score, and eligible for IVT, faster treatment improves functional outcomes [1A]”

I am not going into the detailed indications and contraindications for thrombolysis, as that is beyond the scope of this post

💡

For the complete recommendations, click here

However, it is worth remembering that AHA specifically advises against delaying treatment solely to rule out every possible stroke mimic.

Although rapid treatment inevitably results in some stroke mimics receiving thrombolysis, the incidence of symptomatic intracranial haemorrhage in common mimics such as migraine, seizure, or functional neurological disorder is extremely low (approximately 0.5%) [9].

✅

If the patient receives IV thrombolysis

Do not administer antiplatelet therapy during the first 24 hours. The risk is uncertain and routine use is not recommended [2B N-R] [9].
Aspirin should never be used as a substitute for reperfusion therapy [9].
Repeat brain imaging after 24 hours to exclude haemorrhagic transformation before starting aspirin or DAPT [23].

Step 2. Is it a non-cardioembolic stroke?

Before prescribing antiplatelet therapy, determine why the stroke occurred. This is one of the most important branching points in acute stroke management.

✅

“In patients with non-cardioembolic acute ischemic stroke (AIS) or transient ischemic attack (TIA), antiplatelet therapy is indicated in preference to oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events, while minimising the risk of bleeding [1A]” [9].

In contrast, patients with a cardioembolic stroke generally require anticoagulation rather than DAPT. The common examples are [24]

Atrial fibrillation
Mural thrombus
Mechanical prosthetic heart valves
Hypercoagulable states.

In patients with atrial fibrillation, the AHA guideline advises against routinely combining antiplatelet therapy with oral anticoagulation unless another clear indication exists (such as a recent coronary stent), as the additional bleeding risk generally outweighs the benefit [9].

What about other causes?

Antiphospholipid antibody syndrome and malignancy-associated hypercoagulability: anticoagulation is generally preferred [24].
Extracranial carotid or vertebral artery dissection: either antiplatelet therapy or anticoagulation for approximately 3 months is reasonable [9].

Step 3. Does the patient qualify for DAPT?

Once you've established that the patient has a non-cardioembolic ischemic stroke or high-risk TIA, the next question is whether they qualify for dual antiplatelet therapy (DAPT).

The Canadian Stroke Best Practice guidelines recommend that patients with TIA or minor ischemic stroke being discharged from the Emergency Department should have antiplatelet therapy started before discharge, rather than leaving initiation to outpatient follow-up [23].

✅

Before considering DAPT, remember a few general principles

In patients with acute ischemic stroke (AIS), administration of aspirin is recommended within 48 hours after stroke onset [9].
For patients with non-cardioembolic ischemic stroke or TIA, antiplatelet therapy is preferred over oral anticoagulation for secondary prevention because it reduces recurrent ischemic stroke and other vascular events while minimising bleeding risk [9].

Who is eligible for DAPT?

The strongest recommendation is for patients with:

Minor ischemic stroke (NIHSS ≤3) or
High-risk TIA (ABCD² ≥4)

who present within 24 hours of symptom onset.

✅

For these patients, the AHA recommends [9]

Aspirin plus clopidogrel (after a clopidogrel loading dose),
Continue DAPT for 21 days,
Then transition to single antiplatelet therapy.

What if more than 24 hours have passed?

The 2026 guideline recognises that some patients may still benefit from DAPT beyond the traditional 24-hour window.

Patients with:

Minor ischemic stroke (NIHSS ≤5) or
High-risk TIA (ABCD² ≥4)

who present 24–72 hours after symptom onset

or patients with NIHSS 4–5 presenting within 24 hours

If they have evidence of presumed large artery atherosclerotic disease, including:

≥50% extracranial stenosis,
≥50% intracranial stenosis, or
Imaging evidence suggesting large artery atherosclerosis.

✅

For these patients, the AHA recommends [9]

Aspirin plus clopidogrel (after a clopidogrel loading dose),
Continue DAPT for 21 days,
Then transition to single antiplatelet therapy.

Should I consider ticagrelor?

Not routinely.

The SOCRATES trial [25] compared ticagrelor alone with aspirin in patients presenting within 24 hours of a minor ischemic stroke or high-risk TIA and failed to demonstrate superiority of ticagrelor monotherapy. Consequently, the AHA does not recommend ticagrelor over aspirin as routine monotherapy for these patients [9].

However, ticagrelor combined with aspirin may be considered in selected higher-risk patients.

The AHA gives a Class IIb recommendation for:

Minor ischemic stroke (NIHSS ≤5) or
High-risk TIA (ABCD² ≥6) or
Symptomatic intracranial or extracranial arterial stenosis ≥50%,

provided the patient presents within 24 hours,

✅

These patients may receive ticagrelor (loading dose followed by maintenance) plus aspirin for 30 days.

This recommendation is based largely on the THALES trial [26], which demonstrated a reduction in stroke or death compared with aspirin alone, although this benefit came with an increased risk of major bleeding.

What Matters…

To decide on DAPT, ask these three questions

1️⃣Is this patient eligible for thrombolysis?

The 2026 AHA guidelines recommend that [9]

“In adult patients with AIS with disabling deficits, regardless of NIHSS score, and eligible for IVT, faster treatment improves functional outcomes [1A]”

If the patient receives IV thrombolysis

Do not administer antiplatelet therapy during the first 24 hours. The risk is uncertain and routine use is not recommended [2B N-R] [9].
Aspirin should never be used as a substitute for reperfusion therapy [9].
Repeat brain imaging after 24 hours to exclude haemorrhagic transformation before starting aspirin or DAPT [23].

2️⃣ Is it a non-cardioembolic stroke?

Patients with a cardioembolic stroke generally require anticoagulation rather than DAPT. Common examples are [24]

Atrial fibrillation
Mural thrombus
Mechanical prosthetic heart valves
Hypercoagulable states.

3️⃣Does the patient qualify for DAPT?

“In patients with non-cardioembolic acute ischemic stroke (AIS) or transient ischemic attack (TIA), antiplatelet therapy is indicated in preference to oral anticoagulation to reduce the risk of recurrent ischemic stroke and other cardiovascular events, while minimising the risk of bleeding [1A]” [9].

NIHSS ≤3 or ABCD² ≥4 + within 24 hours
NIHSS ≤5 or ABCD² ≥4 + within 24-72 hours + large-artery atherosclerosis
NIHSS 4–5 + within 24 hours + large-artery atherosclerosis

👉Aspirin + clopidogrel (+loading) x 21 days

NIHSS ≤5 or ABCD² ≥6 or symptomatic arterial stenosis ≥50% + within 24 hours,

👉

What about everyone else?

👉 SAPT

“In patients with AIS, administration of aspirin is recommended within 48 hours after stroke onset to reduce risk of death and dependency.” [9].

Disclaimer : For educational use only — always follow your clinical judgment and local protocols.

📩 Get new posts by email

Want to Read More?

Should I apply a cervical collar to this patient?

Neena Cherian

Hi, I’m an ER physician who’s lived through the chaos and pressure of split-second decisions. I write about practical checklists, simple algorithms, and real-world lessons that help make difficult ED shifts a little easier.